Therefore, if the patient agrees to further treatment, given that this case is ER/PR-positive, HER2-negative, and has a Ki-67 ≤20%—consistent with Luminal A breast cancer—the tumor is likely highly sensitive to endocrine therapy but generally less responsive to chemotherapy. This evidence concerns the gene PGR and breast cancer.